Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis announced that its independent Compensation Committee approved an inducement stock option grant for a new employee. The grant, effective July 1, 2024, allows the employee to purchase 25,000 shares of Curis common stock at the closing price on the grant date. The stock options have a 10-year term and vest over four years, with 25% vesting after the first year and 6.25% vesting every three months thereafter. This grant is outside of the company's existing stock incentive plan and aims to encourage the new employee to join Curis.
Curis announced updated data from its ongoing TakeAim Leukemia study, focusing on emavusertib (CA-4948) treatment for relapsed/refractory AML patients with FLT3 and U2AF1/SF3B1 mutations. The dataset increased from 5 to 30 patients, showing 6 objective responses in 11 FLT3m patients and 4 in 18 SFm patients. Notable responses included complete remission and morphologic leukemia-free state. The data also highlighted increased neutrophil counts in several ongoing patients, indicating potential clinical benefits. These findings will be presented at the ASCO and EHA conferences.
Curis, Inc. (NASDAQ: CRIS) will present updated data from the TakeAim Leukemia study on May 14, 2024. The company focuses on emavusertib (CA-4948), an IRAK4 inhibitor. A conference call will follow the presentation.
Curis, Inc. (NASDAQ: CRIS) provided a business update and financial results for Q1 2024. The company will present clinical data on emavusertib for leukemia patients, updated data for R/R AML, and upcoming milestones for ongoing studies. Financially, Curis reported a net loss of $11.9 million, a decrease in revenue, and increased R&D and G&A expenses. Cash, cash equivalents, and investments totaled $40.7 million as of March 31, 2024.
Curis, Inc. (NASDAQ: CRIS) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The company is focused on developing emavusertib (CA-4948), an IRAK4 inhibitor. Investors can access the call via phone or the company's website.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?
Where can I find more information about Curis Inc.?
